EN DE
Watch SynAct Pharma AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SynAct Pharma AB (SYNACT) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SynAct Pharma AB stock SEK 10.60, price SEK 15.26, that is 30.5% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0008241491

SP SynAct Pharma AB logo Thin data Nov 11, 2026

SynAct Pharma AB

SYNACT · ST
Expensive, weak quality

Our calculation puts a fair price 31% below what the stock costs today.

Quality 40/100
Mixed vs. peers (4/7)
Fair value kr 10.60 · Overvalued
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch SynAct Pharma AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 142.74 kr 5.27 Fair Value kr 10.60 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range kr 5.27 – kr 142.74 · fair‑value band kr 7.95 – kr 13.24 · the kr 15.26 price screens above the kr 10.60 fair value. As of Nov 11, 2026.

Follow SynAct Pharma in your weekly email

Every Wednesday you see whether SynAct Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden.

Show moreShow less

The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy.

It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.

Stock analysis

SynAct Pharma AB (SYNACT) currently trades at kr 15.26, while our estimate is kr 10.60, 31% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 7.95 (bear) to kr 13.24 (bull), the price of kr 15.26 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

SynAct Pharma AB reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −111M SEK in FY2025.

Key figures

Market cap 858M SEK (≈ $87.0M) Micro · EPS (TTM) kr −1.87 · Return on equity −57.7% · Return on assets (EBIT) −91.8% (5-year average) · Free cash flow −97.3M SEK · Net cash 51.6M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −31%, SYNACT screens richer than that median.

Fair Value

Bear kr 7.95 Fair Value kr 10.60 Bull kr 13.24
Price kr 15.26 · Downside -30.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 63
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 35
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 17
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SYNACT screens overvalued: fair value 31% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SynAct Pharma AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −30.5% · Below median
Profitability
Return on assets −50.3% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.51× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SYNACT
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SYNACT
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SYNACT
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SYNACT
argenx SE ARGX $971.55 $908.40 −7% vs SYNACT
CSL Limited CSL A$201.68 A$181.40 −10% vs SYNACT
Moderna, Inc MRNA $250.83 $158.70 −37% vs SYNACT
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SYNACT
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SYNACT
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SYNACT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SynAct Pharma AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SynAct Pharma AB Fair Value". https://www.fairvalue-calculator.com/stock/SYNACT

Frequently asked questions

Is SynAct Pharma AB (SYNACT) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is kr 10.60 versus a price of kr 15.26, about 31% lower (overvalued).
What is the fair value of SYNACT?
Our estimate for SynAct Pharma AB is kr 10.60 (as of Nov 11, 2026), built from audited fundamentals. The current price: kr 15.26.
What is the quality score of SYNACT?
SynAct Pharma AB has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SynAct Pharma AB (SYNACT)?
Our calculated price target is the estimate of kr 10.60 (as of Nov 11, 2026). Cautious scenario kr 7.95, optimistic scenario kr 13.24. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SynAct Pharma AB stock forecast for 2026?
Our estimate puts fair value at kr 10.60, about 31% lower versus a price of kr 15.26 (overvalued). Cautious scenario kr 7.95, optimistic scenario kr 13.24. The calculation is refreshed regularly with new filings.
What is the intrinsic value of SynAct Pharma AB (SYNACT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SynAct Pharma AB it is kr 10.60 per share (as of Nov 11, 2026), against a price of kr 15.26.
Is SynAct Pharma AB stock overvalued or undervalued in 2026?
As of Nov 11, 2026, SYNACT trades above its calculated fair value: price kr 15.26, fair value kr 10.60, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYNACT?
No. The price is what the market pays today (kr 15.26); the fair value is what the company's own numbers justify (kr 10.60). For SynAct Pharma AB the two are kr 4.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is SynAct Pharma AB worth?
The market values SynAct Pharma AB at about 858M SEK (market capitalisation, as of Nov 11, 2026). Per share that is kr 15.26; our models calculate a fair value of kr 10.60 per share.
What do the bullish and bearish scenarios say about SYNACT?
Our models span a range for SynAct Pharma AB: cautious scenario kr 7.95, base kr 10.60, optimistic kr 13.24 per share (as of Nov 11, 2026, price kr 15.26). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SynAct Pharma AB (SYNACT)?
Balance-sheet figures for SynAct Pharma AB (as of Nov 11, 2026): return on equity −57.7%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is SYNACT from its 52-week high?
SynAct Pharma AB trades at kr 15.26, about 37% below its 52-week high of kr 24.20 and 43% above the low of kr 10.66 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 10.60 is for.
Which stocks are comparable to SynAct Pharma AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SynAct Pharma AB stock attractive at the current price?
The data as of Nov 11, 2026: price kr 15.26, calculated fair value kr 10.60 (−31%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. SynAct Pharma AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SynAct Pharma AB (SYNACT)?
The closing price on Nov 10, 2026 was kr 15.26. Our estimate is kr 10.60, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SynAct Pharma AB right now?
The price sits above even our optimistic bull case (kr 13.24). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of SynAct Pharma AB

How large is the market capitalisation of SynAct Pharma AB (SYNACT)?
The market capitalisation of SynAct Pharma AB is 858M SEK (≈ $87.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of SynAct Pharma AB (SYNACT)?
Earnings per share at SynAct Pharma AB are kr −1.87. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SynAct Pharma AB (SYNACT)?
The return on equity (ROE) of SynAct Pharma AB is −57.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SynAct Pharma AB (SYNACT)?
On an EBIT basis the return on assets of SynAct Pharma AB is −91.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does SynAct Pharma AB (SYNACT) generate?
The free cash flow of SynAct Pharma AB is −97.3M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SynAct Pharma AB (SYNACT) hold?
SynAct Pharma AB holds more cash than debt, 51.6M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SynAct Pharma AB in the live analysis

One click puts SynAct Pharma AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.